Vertex Pharmaceuticals Incorporated (LON:0QZU)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 87.09B |
| Revenue (ttm) | 8.72B |
| Net Income (ttm) | 2.73B |
| Shares Out | n/a |
| EPS (ttm) | 10.58 |
| PE Ratio | 31.85 |
| Forward PE | 22.63 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146 |
| Average Volume | 635 |
| Open | 461.01 |
| Previous Close | 456.84 |
| Day's Range | 457.38 - 470.00 |
| 52-Week Range | 362.50 - 519.68 |
| Beta | 0.31 |
| RSI | 44.54 |
| Earnings Date | Feb 12, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling
This "forever" portfolio includes two "Magnificent Seven" stocks that should remain magnificent. It features a conglomerate that's preserving its long-time leader's legacy.
Here's How Much $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 15 years by 5.43% on an annualized basis producing an average annual return of 17.28%. Currently, Vertex Pharmaceutical...
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $438.92, representing a -2.36% change from its previous close.
Vertex Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for VRTX
In trading on Thursday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) crossed below their 200 day moving average of $437.70, changing hands as low as $436.69 per share. Vertex Pharmaceuticals,...
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
These players each are leaders in their specialty areas and have generated billions of dollars in revenue. This list includes a biotech stock, a pharma player, and a medical device company.
CGGO, MU, AON, VRTX: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Capital Group Global Growth Equity ETF (Symbol: CGGO) where we have de...
Vertex Pharmaceuticals Incorporated (VRTX) 44th Annual J.P. Morgan Healthcare Conference Presentation
Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Vertex Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
How Is The Market Feeling About Vertex Pharmaceuticals Inc?
Vertex Pharmaceuticals Inc's (NYSE: VRTX) short interest as a percent of float has fallen 3.54% since its last report. According to exchange reported data, there are now 4.29 million shares sold shor...
Vertex Pharmaceuticals (VRTX) Receives Upgrade to Outperform
Vertex Pharmaceuticals (VRTX) Receives Upgrade to Outperform
Vertex Pharmaceuticals (VRTX) Upgraded by Bernstein to Outperform | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Upgraded by Bernstein to Outperform | VRTX Stock News
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's schedul...
The Best Stocks to Invest $50,000 in Right Now
Alphabet is playing to win in the AI market. Micron is arguably the biggest AI bargain around.
Insider Sell: Ourania Tatsis Sells 4,500 Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: Ourania Tatsis Sells 4,500 Shares of Vertex Pharmaceuticals Inc (VRTX)
$100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 15 years by 6.39% on an annualized basis producing an average annual return of 18.19%. Currently, Vertex Pharmaceutical...
Vertex Pharmaceuticals: The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade)
UBS Lowers Price Target for Vertex Pharmaceuticals (VRTX) to $535.00 | VRTX Stock News
UBS Lowers Price Target for Vertex Pharmaceuticals (VRTX) to $535.00 | VRTX Stock News
Wolfe Research Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News
Wolfe Research Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News
My 10 Top Stocks to Buy to Start the New Year Off Right
This selection of stocks offers interesting buys throughout industries -- from tech to healthcare. Many of these players are trading at bargain levels.
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
In the current market session, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) stock price is at $446.42, after a 1.26% drop. However, over the past month, the company's stock went up by 2.19% , and in th...
The Best Stocks to Invest $1,000 in to Start the New Year Off Right
Alphabet should continue to benefit from a strong AI tailwind in 2026. Vertex Pharmaceuticals has several growth drivers in the new year.
When Phase 3 Data Drops, What Determines A Sustained Rally Vs. A Fading Initial Pop
The biotech sector has always been a high-stakes game where a single clinical trial result can send shares soaring or crashing within hours. As 2025 draws to a close, several companies have demonstrat...
Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise
Vertex Pharmaceuticals (VRTX) is a top biotech pick, with strong earnings, diverse pipelines, and growth prospects. See here for more analysis.
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $453.74, marking a -1.31% move from the previous day.